New data at AAN reinforce clinical benefit of Roche`s OCREVUSTM (ocrelizumab) for relapsing and primary progressive multiple sclerosis
(WorldNews Switzerland)

Basel, 26 April 2017 New data at AAN reinforce clinical benefit of Roche`s OCREVUSTM (ocrelizumab) for relapsing and primary progressive multiple sclerosis OCREVUS rapidly suppressed signs of disease activity in relapsing MS (RMS) patients In patients with early RMS - recently diagnosed and without prior treatment - OCREVUS was superior to Rebif® (interferon beta-1a) in controlling disease activity OCREVUS decreased fatigue versus placebo in people with primary progressive multiple sclerosis (PPMS) In open-label extension studies of over 2,200 patients with RMS and PPMS, OCREVUS continued to show a favourable benefit-risk profile Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new...